Pembrolizumab Plus Lenvatinib in Vulvar Cancer Patients: MITO VULVA-01
Status:
NOT_YET_RECRUITING
Trial end date:
2031-10-01
Target enrollment:
Participant gender:
Summary
MITO VULVA-1 is a prospective, single arm, multi-cohorts, phase II trial that aims to assess the activity and the safety of Lenvatinib plus Pembrolizumab in patients with vulvar cancer. 80 patients will be overall enrolled in the study.Three cohorts are planned